Thursday 16 October, 2025
Introduction: HIV therapeutic vaccines are currently developed with the objective of long-term viral control in the absence of anti-retroviral treatment…
Read morePoster: Drug/Disease Modelling - Infection
Bioavailability and the Variability of Posaconazole Exposure in Healthy Volunteers Using a Population Pharmacokinetic Analysis
Thursday 16 October, 2025
Objectives: Posaconazole is a broad-spectrum, systemic triazole antifungal drug and is widely used for prophylaxis and treatment of invasive fungal…
Read morePharmacokinetics of fluconazole in obese and non-obese adults upon a semi-simultaneous oral and IV study design
Thursday 16 October, 2025
Objectives: Fluconazole is frequently used for the treatment of (invasive) Candida infections. Obesity, and especially morbid obesity, is known to…
Read moreAn integrated population pharmacokinetic analysis for posaconazole oral suspension, delayed-release tablet, and intravenous infusion in healthy volunteers
Thursday 16 October, 2025
Objectives: Posaconazole is widely used for prophylaxis and treatment of invasive fungal diseases. Due to limited and variable absorption for the…
Read morePosaconazole meta-PK analysis upon oral suspension, delayed-release tablet, and intravenous infusion in patients versus healthy volunteers: impact of clinical characteristics and race
Thursday 16 October, 2025
Objectives: We previously developed an integrated population PK model of posaconazole oral suspension (SUS), delayed-release tablet (DR-tablet), and intravenous injection (IV),…
Read moreModeling inflammatory biomarker dynamics during clinical challenge studies with lipopolysaccharide
Thursday 16 October, 2025
Objectives: Sepsis is a life-threatening condition that arises when the body’s response to infection causes injury to its own tissues…
Read morePharmacokinetic variability of isoniazid, and its two major metabolites in patients co-infected with tuberculosis and HIV
Thursday 16 October, 2025
Objectives: Tuberculosis (TB) is the most common cause of death in HIV-infected individuals. Isoniazid in combination with rifampicin, pyrazinamide and…
Read moreModel-based characterization of drug-drug interaction between isoniazid and rifampicin
Thursday 16 October, 2025
Objectives: Rifampicin and isoniazid are the backbone of the current first-line antitubercular therapy. Isoniazid is primarily eliminated by formation of…
Read moreModeling inflammatory biomarker dynamics in human LPS challenge studies using delay differential equations
Thursday 16 October, 2025
Objectives: Bacterial infections and sepsis are associated with production of several inflammatory mediators including cytokines such as tumor necrosis factor α…
Read morePredictive performance of a parasite growth dynamics model for the evaluation of anti-malarial drugs: a case study with mefloquine
Thursday 16 October, 2025
Objectives: A semi-mechanistic pharmacokinetic-pharmacodynamic (PKPD) model was developed to help screen antimalarial compounds in the pre-clinical phase [1]. Assuming that…
Read more